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background: Despite many advances in assisted reproductive techniques (ART), little is known about preferences for technological
developments of women undergoing fertility treatments. The aims of this study were to investigate the preferences of infertile women under-
going ART for controlled ovarian stimulation (COS) treatments; to determine the utility values ascribed to different attributes of COS treat-
ments; and to estimate women’s willingness to pay (WTP) for COS.
methods: A representative sample of ambulatory patients ready to receive, or receiving, COS therapies for infertility were recruited
from seven specialized private centres in six autonomous communities in Spain. Descriptive, inferential and conjoint analyses (CA) were
used to elicit preferences and WTP. Attributes and levels of COS treatments were identiﬁed by literature review and two focus groups
with experts and patients. WTP valuations were derived by a combination of double-bounded (closed-ended) and open questions and con-
tingent ranking methods.
results: In total, 160 patients [mean (standard deviation; SD) age: 35.8 (4.2) years] were interviewed. Over half of the participants
(55.0%) had a high level of education (university degree), most (78.8%) were married and half (50.0%) had an estimated net income of
.E1502 per month and had paid a mean (SD) E1194.17 (E778.29) for their most recent hormonal treatment. The most frequent
causes of infertility were related to sperm abnormalities (50.3%). In 30.6% of cases, there were two causes of infertility. The maximum
WTP for COS treatment was E800 (median) per cycle; 35.5% were willing to pay an additional E101–E300 for a 1–2% effectiveness
gain in the treatment. Utility values (CA) showed that effectiveness was the most valued attribute (39.82), followed by costs (18.74),
safety (17.75) and information sharing with physicians (14.93).
conclusions: WTP for COS therapies exceeds current cost. Additional WTP exists for 1–2% effectiveness improvement. Effective-
ness and costs were the most important determinants of preferences, followed by safety and information sharing with physicians.
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Introduction
Willingness to pay (WTP) methods have generally been used to place
a monetary value on health beneﬁts in the context of a speciﬁc inter-
vention, to elicit patients’ values and preferences for different interven-
tions and to enable a comprehensive assessment of the perceived
beneﬁts (Herath et al., 2007). Technological innovations have greatly
improved the therapeutic options of infertile women who seek
medical assistance to achieve pregnancy (Ryan et al., 2004). Among
such developments, the emergence of recombinant forms of human
follicle-stimulating hormone (r-hFSH) suitable for subcutaneous injec-
tion has made treatments simpler and more comfortable than the
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Advanced Access publication on May 10, 2011 doi:10.1093/humrep/der139traditional syringe and needle (Harlin et al., 2000). Self-injection with a
pen device has been shown to be safe and easy, more convenient and
less painful for the patient, to require lower FSH doses, to be less
time-consuming and to shorten treatment duration (Platteau et al.,
2003). Several attributes of therapy, such as successful pregnancy
rate, ease of device use and convenience of treatment administration
have been acknowledged as key determinants of patients’ decisions
about treatment (Porter et al., 2008). Aspects related to the
patient–doctor relationship, such as information handling and shared
decision-making, may also inﬂuence patients’ choice of fertility treat-
ment (Malin et al., 2001). Little is known, however, about the impor-
tance that women undergoing fertility treatment assign to the
individual characteristics of their treatment.
Coverage of interventions and services in fertility has been internation-
ally characterized by low public funding, while the appropriate level and
source of funds for assisted reproductive technology (ART) procedures
have been controversial in most developed societies (Olsen and Smith,
2001). Funding for infertility care has been distinguished by its reliance on
higher user copayment compared with other health services (Marra
et al., 2005). In Spain, although the National Health System covers
ART in women ,40 years of age, long waiting lists in the public
sector make many infertile women seek private care (Matorras et al.,
2007). Only Catalonia covers medication costs during three cycles
when reproductive therapies are undertaken privately (Bosser, 2009).
This study aimed to: (1) investigate the preferences of infertile
women undergoing ART for controlled ovarian stimulation (COS)
treatments; (2) determine the utility values ascribed to different attri-
butes of COS treatments; and (3) estimate women’s WTP for COS.
Materials and Methods
Study design and methods
An observational, longitudinal, prospective, multicentre study was
designed to determine women’s preferences for hormone fertility treat-
ments in the private health sector in Spain. Two complementary tech-
niques were applied to elicit preferences: WTP and conjoint analysis
(CA). WTP is the maximum amount of money a person would be
willing to pay, sacriﬁce or exchange for goods, in this case, for a beneﬁt
in their health state (Hanley et al., 2003). The philosophy behind this tech-
nique is that the maximum amount of money a person is willing to pay for
a healthcare gain is an indicator of the value of that gain to that person. CA
serves to determine how individuals value different features that constitute
a particular health product or service (Ryan and Farrar, 2000). It seeks to
establish what combination of a limited number of attributes is most inﬂu-
ential on respondents’ choice or decision-making. The implicit value
(utility) of the individual elements making up the treatment modality can
be determined by analysing how participants deﬁne their preferences for
the characteristics of the product.
WTP was assessed in two complementary ways: (1) a structured inter-
view was conducted to directly ask patients about their WTP for a deﬁned
COS treatment; (2) the cost of treatment was included as an attribute in
the CA. It was possible to directly assess the importance and the utility
value assigned to the costs of treatments in relation to the other charac-
teristics of treatments.
Experts in fertility were invited to form a study advisory board to give
informed support to the project.
The deﬁnition of the content of the WTP interview and the selection of
the attributes of treatments and their levels were conducted in three
stages: ﬁrst, a literature review identiﬁed a preliminary set of attributes
and their levels; second, a focus expert group selected the treatment
characteristics that are most meaningful in clinical practice and estimated
the average price that their patients normally paid for their COS treat-
ments; third, structured telephone interviews with infertility patients
further deﬁned treatment characteristics from their perspective.
The list of attributes initially identiﬁed in the literature and presented to
the experts, as well as the arguments given by them to either refuse or
include each characteristic of treatment in the CA are provided in the
Supplementary information. A general consensus was sought on the
most deﬁnitive attributes that inﬂuence treatment decisions.
Patients’ perspectives were obtained during the telephone interview;
eight participants were asked to identify the characteristics of COS treat-
ment that drive their preferences, as well as to estimate the average price
that they have usually paid for their hormonal fertility treatments. Their
experiences from receiving COS treatment, as well as being members of
the Spanish National Association for Infertility Problems (ASPROIN), pro-
vided valuable additional information to the advisory board. The inter-
views were conducted by an experienced researcher (S.P.), lasted no
longer than 15 min, and were recorded on audiotape for subsequent
content analysis. Finally, a set of attributes and their levels were deﬁned,
based on the ones recognized by both experts and patients as the most
relevant to determine treatment choices. As a result, COS was described
in terms of ﬁve attributes, which were broken down into different levels
(Table I). All levels of treatment attributes were combined, and an orthog-
onal fractional design was used to form a set of eight scenarios. A similar
criterion of general agreement between experts and patients was applied
to deﬁne the average price for a cycle of hormonal fertility treatment to be
applied in the WTP interview.
........................................................................................
Table I Description of attributes with their levels.
Attribute Levels Description
Safety Safer Smaller risk, although of no
consequence, of causing
infections or allergies
Less safe Higher risk, although of no
consequence, of causing
infections or allergies
Effectiveness More effective 1–2% higher rate of a
successful pregnancy
Less effective Lower rate of a successful
pregnancy
Administration of
treatment
More friendly
administration of
treatment
Treatment administration
does not interfere with
social and work activities
Less friendly
administration of
treatment
Treatment administration
interferes with social and
work activities
Price ,E1000 Per cycle of ovarian
stimulation E1000–E1500
E1500–E2000
.E2000
Patient–doctor
information sharing
Your physician informs you about possible
alternative treatments and involves you in decisions
about treatments to follow
Your physician does not inform you about possible
alternative treatments and does not involve you in
decisions about treatments to follow
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interview
As part of the study ﬁeld work, a structured, two-part (WTP and
CA) patient interview was designed based on the ﬁndings gathered
from the literature, the focus expert group and the telephone inter-
views. The interview was conducted by a trained researcher (S.P.),
not known to the participants, and took place either before or
after the patients’ routine medical appointment for a maximum of
40 min. First, the patients were presented with a description of the
product being evaluated and were asked about their WTP for a pre-
viously deﬁned amount that reﬂected the current price of treatments
in the market, which was agreed by experts and patients. Their
maximum WTP was established from a combination of double-
bounded (closed-ended) and open questions (Fig. 1). In those situ-
ations where participants had difﬁculty expressing a maximum WTP,
the technique of ﬁrst refusal price was employed in a way such that
all women ﬁnally reported a maximum amount. Additionally, they
were asked about the number of times throughout the year they
would be prepared to pay the maximum amount stated and the per-
centage of treatment costs they considered that public healthcare ser-
vices should cover. Three ﬁnal questions explored the extra quantity
of money participants were willing to pay for individual characteristics
of treatments, such as injection comfort, tolerance and effectiveness.
The interview also included socio-demographic questions, open ques-
tions on the current price that patients pay for hormonal treatments
per cycle of COS and a visual analogue scale (VAS) to estimate the
proportional value assigned to the hormonal therapies in relation to
the total amount paid for ART.
Second, respondents were shown a set of eight scenarios, written on a
paper card, and asked to order them from ‘the most’ to ‘the least’ pre-
ferred. Each scenario was made up of a unique combination of treatment
features. Each scenario was similar enough that participants saw them as
close substitutes, but sufﬁciently dissimilar that they could clearly deter-
mine a preference.
Sample size
To the authors’ best knowledge, there are no references in the literature
on assessments of the preferences of infertile women undergoing COS.
Sample size was estimated accepting a maximum uncertainty of 50%,
and assuming an accuracy of 8% with a 95% conﬁdence interval (CI).
Under these assumptions, a sample size of 150 patients was required.
Assuming possible losses of 10%, the sample size was ﬁxed on 165
patients.
Study setting and participants
All participants were women, and were outpatients at private fertility
clinics in different autonomous communities in Spain. They were identiﬁed
at each study site by the healthcare team and were consecutively recruited
into the study (non-random, convenient sampling) if they were aged 18
years or older, had been, or were about to be, on hormone fertility treat-
ment and gave written, informed consent to participate in the project.
Possible candidates were excluded if they were participating in a clinical
trial at the time of the study, were oocyte donors or were unable to prop-
erly respond to the interviews’ tasks for any reason, including the need for
the cultural adaptation of the research tools. Treatments were prescribed
according to usual clinical practice.
Data analysis
A statistical descriptive analysis was performed to investigate the social,
demographic and clinical characteristics of the women that took part in
the study. WTP was estimated from the answers given about their
WTP the current price of treatments, about the maximum amount of
money that they said they would be willing to pay for the product and
Figure 1 Type of questions used to elicit WTP.
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characteristics of treatments, such as effectiveness, injection comfort and
local tolerance. Descriptive analyses were performed. Relations between
these and the rest of the social and clinical variables were explored
using hypothesis tests and multiple linear regression analysis.
An orthogonal fractional factorial design (SPSS Conjoint 16.0) was used
to deﬁne the scenarios for the CA. The resulting orthogonal matrix cap-
tured the principal effects of each level of attributes. It was assumed
that interactions between levels of the same attribute were meaningless.
The ordering method was applied to determine the preferences of partici-
pants, and a mean position value was estimated for each scenario. Analysis
of the scenario order gave a utility score and represented the partial con-
tribution of each level of the attributes in the determination of prefer-
ences. Linear regression analysis was employed to estimate the utility
values assigned to each level of attributes. The mathematical expression
for the model is as follows:
Y = b0 + b1(Attribute1)+b2(Attribute2)+b3(Attribute3)
+ b4(Attribute4)+b5(Attribute5)+e
where Y is the respondent’s preference, b0 is the constant or the intercept
term, b1 to b5 are part-worth utilities (or simply utility values) and e is an
error term. All the dichotomous (two levels) attributes were codiﬁed
as +1 for their ‘best level’ (safer, 1–2% more effective, more comfortable,
decision shared with physician) and as 21 for their ‘worst level’ (less safe,
less effective, less comfortable administration, decision not shared with
physician). Attribute ‘cost’ was codiﬁed with the labels 1:4.
Higher utility values implied a greater preference for that level of attri-
bute. Additionally, the coefﬁcients of importance of all attributes were
estimated. The total importance of a set of conjoint attributes is always
calculated to sum up to 100%. The importance of an individual conjoint
attribute is determined by the span of the utility levels for each attribute
compared with the utility spans for the other attributes. As a result, it
was possible to establish whether the attribute had an inﬂuence on the
preference for a given COS treatment, as well as the relative importance
assigned to the different attributes for making treatment choices. It was
established that preferred scenarios had higher utility values derived
from their attributes compared with less preferred scenarios.
Results
Seven private clinics in six autonomous communities in Spain took part
in the study. A total of 171 patients were initially recruited into the
study. However, four participants declined to take part due to
emotional distress and seven were excluded due to their donor con-
dition. Therefore, study results are based on a sample of 160 partici-
pants (Andalusia, n ¼ 22; Asturias, n ¼ 31; Balearic Islands, n ¼ 17;
Canary Islands, n ¼ 27; Madrid, n ¼ 19; Valencia, n ¼ 44).
Social and demographic characteristics
Table II summarizes the social and demographic characteristics of the
studied sample. The mean [standard deviation (SD)] age of partici-
pants was 35.8 (4.2) years (range: 22–46 years). The majority of
participants were married (78.8%) and employed (68.8%), with
more than half (55.0%) having a high level of education (university
degree). Half of the participants (50.0%) had an estimated net
income of .E1502 per month; of these, 18.4% had a net income
ranging between E1804 and E2404 per month.
Clinical characteristics
The most frequent causes of infertility were related to sperm abnorm-
alities (50.3%), followed by ovulatory dysfunction (19.6%). In about
one-third of participants (30.6%), there were two causes of infertility,
while in 25.6%, the cause of infertility could be attributed to the
couple. Mean (SD) length of follow-up in the same clinic was 8.2
(11.4) months (range: 0–72 months), while the mean (SD) length of
time patients were on COS treatment was 8.0 (11.5) months
(range: 0.3–65.6 months). At the time of the study, 56.6%
(81/143) of patients were receiving hormonal treatment. The most
commonly prescribed treatment was r-hFSH (72.7%), followed by
the urinary human FSH/luteinizing hormone combination (29.6%).
IVF was the technique most commonly indicated (85.3%) and the
gonadotrophin-releasing hormone antagonist protocol for ovarian
stimulation was the most frequently prescribed treatment
scheme (53.1%).
Willingness to pay
The mean (SD) amount of money that had been paid by patients
(n ¼ 145) for their most recent hormonal treatment was E1194.11
(E778.29; range: E30–E5000). In a VAS representing percentages
(0–100%), patients were asked to indicate what proportion of the
........................................................................................
Table II Social and demographic characteristics of the
studied population.
Numberof
patients
(n 5 160)
Percentage
of patients
(%)
Accumulated
percentage (%)
Education
No school
attendance
1 0.6 0.6
Primary school 22 13.8 14.4
Secondary
school
26 16.3 30.6
College/
technical
school
23 14.4 45.0
University 88 55.0 100.0
Marital status
Single 11 6.9 6.9
Married 126 78.8 85.6
Partnered 22 13.8 99.4
Divorced 1 0.6 100.0
Job situation
Employed 110 68.8 68.8
Self-employed 21 13.1 81.9
Permanent
sick leave
1 0.6 82.5
Temporary
sick leave
1 0.6 83.1
Unemployed 13 8.1 91.3
Homemaker 11 6.9 98.1
Student 3 1.9 100.0
Willingness to pay for hormone fertility treatment 1793total cost of ART they would be willing to devote exclusively to COS.
In this way, it was possible to indirectly estimate the relative impor-
tance given to hormone therapies within the entire ART. VAS
measurements showed that as many as 84.1% of participants would
be willing to pay up to 60% of the total price of the current fertility
treatment to COS alone. On average, women who underwent infer-
tility treatment because of male factor infertility would be willing to
pay up to 32.18% of the total price, while women who sought treat-
ment due to female infertility would pay up to 42.18% of the total
price. Finally, women with infertility problems attributed to both part-
ners would pay up to 50.36% of the total ART cost to COS. A Tukey
test detected statistically signiﬁcant differences between the mean
percentage of women in the group with male factor infertility and
the group with infertility related to both partners (F ¼ 7.45,
P ¼ 0.0008). The group with infertility related to both partners
would assign a higher proportion of the total ART costs to COS
than women with male-related infertility.
As many as 45.0% (72/160) of patients would pay E1200 per cycle
of COS with a series of characteristics: including a guarantee of a
1–2% gain in the probability of a successful pregnancy; a preﬁlled
pen that would make the administration of treatment easier, more
comfortable, more reliable, quicker and more discrete; a 50%
decrease in the chances of redness and discomfort in the injection
site; safer, in terms of smaller risks of causing allergies or infections;
and a 1–2% probability of developing ovarian hyperstimulation
syndrome. Most of the patients (62.4%) who were willing to pay
E1200 per COS cycle had a higher level of education (university
degree) and the majority (86.3%) were undergoing COS at the time
of the interview.
The median maximum amount of money participants were willing
to pay for their COS therapy was E800 per cycle (mean:
E1442.29; SD: E4093.57; range: E0–E50 000); the majority of par-
ticipants (76.4%) would pay this up to four times in a year (mean: 5.53;
SD: 10.86; range: 1–77). All participants stated that public healthcare
services should cover part of the hormonal treatment costs; a majority
(66.9%) believed that this funding should cover up to 80% of the
overall costs of COS (mean: 73.37%; SD: 21.29%; median: 75.00%;
range: 30–100%).
The maximum amount of money that participants would be willing
to pay was independent of their age (P ¼ 0.36), marital status
(P ¼ 0.27), employment situation (P ¼ 0.97) or net monthly house-
hold income (P ¼ 0.85). It was also independent of the length of
time patients were receiving fertility treatment (P ¼ 0.62), their con-
dition of already being on treatment at study entry (P ¼ 0.26) and
the treatment scheme they were on (P ¼ 0.89). Multiple regression
analysis showed that changes in the maximum amount of money
that participants would be willing to pay for hormone fertility treat-
ments could not be explained by participants’ age, marital status,
employment situation, education level or net monthly income (P ¼
0.25). Its variation could neither be explained by the causes of inferti-
lity, whether the origin of infertility related to the male, the female or
the couple, the length of time patients had spent on fertility treatment
or the ART being indicated (P ¼ 0.22).
In relation to the three characteristics of treatments assessed indi-
vidually, 35.5% of participants would pay an additional E101–E300
for a 1–2% increase in the successful pregnancy rate. Other features
of treatment such as comfort in the administration and local tolerance
of injections were given little value: more than half of participants
(62.5%, comfort; 66.3%, tolerance) would pay no extra money for
gains in these attributes (Table III).
Conjoint analysis: utility and importance
values
A total of ﬁve attributes of COS (safety, effectiveness, comfort of the
administration, cost and physicians’ shared decisions with patients)
and their levels were assessed. The highest utility value was assigned
to effectiveness (1.49) understood as 1–2% higher probability of
having a successful pregnancy, followed by safety (0.62) and shared
decisions with physicians (0.41) (Fig. 2). Comfort in the administration
of treatment was given a lower utility value (0.25) than the three pre-
vious attributes. All ranges of costs being analysed received negative
values (,E1000 per cycle of COS: 20.47; E1000–E1500: 20.95;
E1500–E2000: 21.42; .E2000: 21.90). Table IV shows the 95%
CI for each estimated utility value.
The effectiveness of treatment was considered the most important
attribute (39.82). Costs were scored in second place (18.74), followed
by safety (17.75). Information sharing with physicians (14.93) was
ranked in fourth place. Comfort of treatment administration (8.73)
was considered the least important feature of COS treatment. All
differences in values of importance were statistically signiﬁcant
except for safety versus costs (P ¼ 0.21); no signiﬁcant differences
were found between the importance given to both of them. There
was a strong correlation between the observed and the estimated
preferences (R ¼ 0.99; P , 0.0001).
Scenarios
Table V shows statistical information on the order of preference
attributed to the eight suggested scenarios. Ranked from the most
to the least favoured by participants, scenario 1 was the most
.................................................................
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Table III Willingness to pay for three individual
advantages of controlled ovarian stimulation therapy.
Maximum
amount
willing to
pay, E
(range)
Patients in each range, n (%)
Preﬁlled
pen
(comfort)
50% smaller
chance of
redness on
the injection
site
(tolerance)
1–2% higher
rate of a
successful
pregnancy
(effectiveness)
0 100 (62.5) 106 (66.3) 23 (14.7)
1–50 19 (11.9) 29 (18.1) 16 (20.3)
51–100 24 (15.0) 14 (8.8) 37 (23.7)
101–300 14 (8.8) 8 (5.0) 55 (35.5)
301–500 2 (1.3) 3 (1.9) 16 (10.3)
501–1000 1 (0.6) 0 9 (5.8)
1001–2000 0 0 3 (1.8)
.2000 0 0 1 (0.6)
1794 Palumbo et al.preferred (preference position: median 1.00). It was chosen in ﬁrst
place by 95.6% of the participants (n ¼ 153). The next most desirable
scenario was number 8 (preference position: median 3.00); 43.1% of
patients preferred it in second place (n ¼ 69). The least favoured was
scenario 3 (preference position: median 6.50), with 36.3% of partici-
pants placing it as the last option (n ¼ 58). Scenarios 5, 7 and 8 were
.............................................................................................................................................................................................
Table IV Conﬁdence intervals for utility values.
Attributes of treatment Levels of attributes Utility value
estimates
95% conﬁdence
intervals
Safety Less safe 20.623 [20.7222, 20.5232]
Safer 0.623 [0.5232, 0.7222]
Effectiveness Less effective 21.491 [21.5952, 21.3987]
1–2% more effective 1.491 [1.3987, 1.5952]
Administration of treatment Less comfortable administration 20.252 [20.3086, 20.1913]
More comfortable administration 0.252 [0.1913, 0.3086]
Patient–doctor information sharing and
decision-making
Information and decision not shared with
patient
20.414 [20.5150, 20.3023]
Information and decision shared with patient 0.414 [0.3023, 0.5150]
Price ,E1000/cycle 20.475 [20.5491, 20.4053]
E1000–E1500/cycle 20.950 [21.0263, 20.8826]
E1500–E2000/cycle 21.425 [21.5036, 21.3598]
.E2000/cycle 21.901 [21.9808, 21.8371]
Figure 2 Utility values assigned to the levels of attributes of treatment.
......................................................................................................................................................
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Table V Ranking of participants’ preferences for the suggested scenarios (n 5 160).
Scenarios
12345678
Mean 1.26 6.35 6.15 5.86 4.79 4.65 4.00 2.99
Median 1.0 6.00 6.50 6.00 5.00 4.00 4.00 3.00
Standard deviation 1.28 1.21 1.87 1.76 1.83 1.78 1.72 1.33
Minimum 1.00 1.00 1.00 1.00 2.00 1.00 2.00 2.00
Maximum 8.00 8.00 8.00 8.00 8.00 8.00 8.00 8.00
Willingness to pay for hormone fertility treatment 1795never placed in ﬁrst place by participants. Table VI provides details of
the above three scenarios.
Discussion
Women’s preferences for COS in the context of ART were elicited
using two complementary techniques: WTP and CA. The simul-
taneous use of both techniques allowed a direct estimate of the
maximum amount of money participants were willing to pay for
COS treatment that offered certain gains in effectiveness, safety and
comfort, as well as an assessment of the relative importance and
utility values assigned by patients to costs compared with the other
therapy attributes. Assessment using both techniques showed that
treatment costs were less important to patients if the chances of a
successful pregnancy were to be increased.
Higher pregnancy rates were paramount in deﬁning patients’ prefer-
ences for fertility treatments. The WTP interview showed that
patients would be willing to pay an additional amount of money for
a 1–2% improvement in effectiveness, while the CA demonstrated
that patients would be ready to trade-off treatment costs for gains
in effectiveness and safety. These ﬁndings are congruent with results
from other studies. For instance, early reports found that a 10%
chance of having a child through IVF in the event of infertility deter-
mined couples’ WTP a stated amount of money under various
assumptions on the probability of success (Neumann and Johannes-
son, 1994). It has also been reported that patients with polycystic
ovary syndrome would prefer electrocautery of the ovaries over ovu-
lation induction with r-hFSH if both treatment strategies resulted in
similar pregnancy rates (Bayram et al., 2005). However, most patients
were willing to trade off their preference for increased effectiveness.
The percentage of patients who preferred electrocautery over
r-hFSH declined when the difference in theoretical pregnancy rates
was .5% in favour of r-hFSH. It has also been found that infertile
couples would give high economic priority to infertility treatment
and that they would pay more for a child than the calculated direct
cost (Devlin and Parkin, 2003), which reﬂects the high value attributed
to conceiving a child.
In this study, the maximum amount of money that participants
would pay for their hormone fertility therapies was independent of
their age, education, marital status and net monthly income. These
results differ from other ﬁndings in which WTP has been positively
associated with education, income and beliefs, and the ideological
acceptance of healthcare (Cookson, 2003). However, it could be
argued that the women being interviewed had already made their
decision to seek medical treatment for their fertility problem, were
prepared to pay its costs and, therefore, their net monthly income
had no particular inﬂuence on their readiness to fund COS. Accord-
ingly, it has been reported that income has an impact on the decision
to seek medical assistance, especially ART, which is expensive and least
likely to be covered by insurance (Ordovensky Staniec and Webb,
2007). Net income appears to be signiﬁcant in terms of decreasing
the likelihood that poorer women will seek fertility treatment, but it
does not seem to considerably increase the chances that relatively
well-off women will do so (Hughes and Giacomini, 2001).
Shared information and decision-making on therapies with the
specialist was also investigated as it has been reported to substan-
tially inﬂuence patients’ preferences for treatments (Say and
Thomson, 2003). In this study, participants gave more importance
and a higher value to information sharing than to comfort in the
administration of therapies, implying that women would exchange
simplicity and minor discomfort in the application of treatments
for a more reassuring communication with their treating physician.
Furthermore, unsatisfactory encounters with healthcare pro-
fessionals had been reported to be the main reasons for dissatisfac-
tion amongst infertile women seeking medical care, and they had
been frequently referred to as one of the most negative treatment
experiences (Malin et al., 2001).
The value given to the use of a preﬁlled pen device to self-
administer treatment was assessed in terms of impact on daily life.
Patients felt there would be little interference with everyday social
and work activities. This attribute was the weakest determinant of pre-
ferences compared with the other treatment characteristics explored.
Participants would exchange the commodity that offers a preﬁlled pen
device for gains in effectiveness, safety, costs and communication with
their treating physicians. In studies that solely assessed different mod-
alities of therapy administration, the pen device was chosen over other
dosing methods due to its perceived beneﬁts in terms of gains in efﬁ-
ciency (Bruynesteyn et al., 2005). Attributes that have usually favoured
the use of a pen device include a faster preparation, higher conﬁdence
of accurate dosing and the need for fewer dose adjustments (Porter
et al., 2008). According to our ﬁndings, these valuable attributes
.....................................................
........................................................................................
Table VI Preferred scenarios.
Most preferred scenarios Least preferred
scenario
Scenario 1 Scenario 8 Scenario 3
Safer (minor risk,
insigniﬁcant, of
causing infections or
allergies)
Less safe (higher
risk, although
insigniﬁcant, of
causing infections or
allergies)
Less safe (higher risk,
although insigniﬁcant, of
causing infections or
allergies)
More effective
(1–2% higher rate
of a successful
pregnancy)
More effective
(1–2% higher rate
of a successful
pregnancy)
Less effective (lower rate
of a successful pregnancy)
More friendly
administration of
treatment
(treatment
administration does
not interfere with
social and work
activities)
More friendly
administration of
treatment
(treatment
administration does
not interfere with
social and work
activities)
More friendly
administration of
treatment (treatment
administration does not
interfere with social and
work activities)
Price: ,E1000 per
cycle of ovarian
stimulation
Price: E1500–
E2000 per cycle of
ovarian stimulation
Price: .E2000 per cycle
of ovarian stimulation
Your physician
informs you about
all possible
alternative
treatments and
involves you in all
decisions about the
treatments to follow
Your physician does
not inform you
about possible
alternative
treatments and does
not involve you in
decisions about
treatments to follow
Your physician informsyou
about all possible
alternative treatments and
involves you in all decisions
about the treatments to
follow
1796 Palumbo et al.seem to lose relevance when other aspects of treatment are
considered.
Results show that both experienced patients and those about to
start their ﬁrst COS cycle would prefer to be treated with the most
effective hormones. This outcome seems reasonable for those
patients who have devoted not only ﬁnancial and time resources,
but also emotional involvement because of lack of effectiveness of pre-
vious cycles: once they have allocated so many hopes and resources to
ineffective treatments, they are ready to allocate additional ﬁnancial
resources even for marginal improvements (as low as 1–2%) in the
pregnancy odds. Despite not having undergone these experiences pre-
viously, ﬁrst time patients also gave priority to effectiveness. An econ-
omic interpretation of this result would be that improvements in
pregnancy probabilities imply a lower risk of requiring additional
investments of both time and money for subsequent treatment cycles.
This information about patients’ preferences becomes extremely
valuable for healthcare professionals as this knowledge may allow
them to improve not only the success rates of their therapies, but also
other health-related quality of life outcomes related to patient satisfac-
tion.Alltheseoutcomesconstituteacomprehensivemeasureofquality
of healthcare and, thus, are valuable sources of information for patients
and professionals. In accordance with this, ﬁndings reported from pre-
vious studies have shown that respectful communication, appropriate
information, support and conﬁdence in healthcare professionals are
highly valued in a clinical situation where outcomes are uncertain and
emotional involvement is high (Redshaw et al., 2007).
In summary, this study reports the attributes that most strongly
determine women’s preferences for hormone fertility therapies in
patients undergoing ART in the private sector in Spain. Respondents
attributed the highest preference values to the effectiveness of the
fertility treatment. Although important, other attributes of the inter-
vention, such as gains in safety, comfort in their application and
saving costs came behind the greater chance of success in conceiving
a child. The information gathered may help clinicians and policy-
makers to make more informed decisions in fertility interventions,
taking into account patients’ views on the value of treatments.
Despite the lack of a single, best approach to be applied, conjoint-
based methods and WTP are among the quantitative techniques
recommended to gain public opinion and preferences on healthcare
interventions (Ryan et al., 2001).
Implications for future research
According to this study, WTP and CA appear to be useful tools in
understanding how people value the beneﬁts of reproductive treat-
ments. A similar approach could be used to investigate, for instance,
preference differences of the male partners of women undergoing fer-
tility treatment or in patients from countries where IVF is differently
reimbursed. Further research is needed to unravel how patients’ pre-
ferences are shaped and what factors inﬂuence the high importance
given to the effectiveness of fertility therapies.
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